Loading...
Thumbnail Image
Item

Traditional and new composite endpoints in heart failure clinical trials: Facilitating comprehensive efficacy assessments and improving trial efficiency

Citations
Google Scholar:
Altmetric:
Principal Supervisor
Co-Supervisor
Degree Name
Abstract
Composite endpoints are commonly used as the primary measure of efficacy in heart failure clinical trials to assess the overall treatment effect and to increase the efficiency of trials. Clinical trials still must enrol large numbers of patients to accrue a sufficient number of outcome events and have adequate power to draw conclusions about the efficacy and safety of new treatments for heart failure. Additionally, the societal and health system perspectives on heart failure have raised interest in ascertaining the effects of therapy on outcomes such as repeat hospitalization and the patient's burden of disease. Thus, novel methods for using composite endpoints in clinical trials ( e.g. clinical status composite endpoints, recurrent event analyses ) are being applied in current and planned trials. Endpoints that measure functional status or reflect the patient experience are important but used cautiously because heart failure treatments may improve function yet have adverse effects on mortality. This paper discusses the use of traditional and new composite endpoints, identifies qualities of robust composites, and outlines opportunities for future research.
Keywords
heart failure, clinical trial, endpoint determination, surrogate endpoints
Publication Date
2016
Type
Journal article
Published In
European Journal of Heart Failure
Volume
18
Issue
5
Article Number
Start page
End page
Page Range
482-489
ACU Organisational Area
Related
Open Access Status
File Access
Controlled
License
License Link
Rights Statement
ICIP
Funded By
Full Citation
Further Information